The treatment for advanced stage
non-small cell lung cancer (NSCLC) often includes
platinum-based
chemotherapy and IR.
Cisplatin and IR combination
therapy display schedule and dose-dependent synergy, the mechanism of which is not completely understood. In a series of in vitro and cell culture assays in a NSCLC model, we investigated both the downstream and direct treatment and damage effects of
cisplatin on NHEJ catalyzed repair of
a DNA DSB. The results demonstrate that extracts prepared from
cisplatin-treated cells are fully capable of NHEJ catalyzed repair of a
DSB using a non-
cisplatin-damaged
DNA substrate in vitro. Similarly, using two different host cell reactivation assays, treatment of cells prior to transfection of a linear, undamaged reporter plasmid revealed no reduction in NHEJ compared with untreated cells. In contrast, transfection of a linear GFP-reporter plasmid containing site-specific,
cisplatin lesions 6-bp from the termini revealed a significant impairment in
DSB repair of the
cisplatin-damaged
DNA substrates in the absence of cellular treatment with
cisplatin. Together, these data demonstrate that impaired NHEJ in combined
cisplatin-IR treated cells is likely the result of a direct effect of
cisplatin-DNA lesions near a
DSB and that the indirect cellular effects of
cisplatin treatment are not significant contributors to the synergistic cytotoxicity observed with combination
cisplatin-IR treatment.